Media Advisory: Ribbon Cutting Ceremony for new Zoetis facility in Lincoln, NE, to expand manufacturing capabilities and bring more jobs to Lincoln
August 04 2023 - 1:17PM
Business Wire
Zoetis, the world’s leading animal health company, is pleased to
invite members of the media to attend a ribbon-cutting event to
mark the official opening of our new monoclonal antibodies (mAbs)
expansion, which will enable the site to increase production of
products that control osteoarthritis pain in dogs and cats – our
largest growing area of need for pet care customers. The site will
also be a home for future innovation and serve as a Veterinary
Medicine R&D registration facility for the company.
The event will take place on August 9 at 2:00 PM CT at the
following location:
Zoetis 601 W Cornhusker Hwy Lincoln, NE
68521
During the outdoor ceremony, local officials, including Senator
Pete Ricketts, Mayor Gaylor Baird and key company leaders including
Zoetis CEO Kristin Peck, and President of Global Manufacturing and
Supply, Nick Ashton, will be present to share insights into the new
facility, potential impact on animal health and what the expansion
brings to the local Lincoln community.
The program for the event includes:
- Welcome address by Kristin Peck, CEO of Zoetis
- Remarks by local officials on the significance of the new
facility for the community
- Photo opportunity with local officials, Kristin Peck and other
company leaders outside the facility; interior site images will be
available on request (access to facility is restricted to maintain
a sterile environment)
- Exclusive Q&A session with key personnel
Registration information:
Please register to attend by emailing:
Robyn.Velardo@zoetis.com.
We kindly request that media representatives check in and
present press credentials at site security upon arrival.
A press release with event details and additional images will be
available following the live event.
About Zoetis
As the world’s leading animal health company, Zoetis is driven
by a singular purpose: to nurture our world and humankind by
advancing care for animals. After innovating ways to predict,
prevent, detect, and treat animal illness for more than 70 years,
Zoetis continues to stand by those raising and caring for animals
worldwide -- from veterinarians and pet owners to livestock farmers
and ranchers. The company’s leading portfolio and pipeline of
medicines, vaccines, diagnostics and technologies make a difference
in over 100 countries. A Fortune 500 company, Zoetis generated
revenue of $8.1 billion in 2022 with approximately 13,800
employees. For more information, visit www.zoetis.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230804358274/en/
Media: Robyn Velardo 973.936.0481 robyn.velardo@zoetis.com
Zoetis (NYSE:ZTS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Zoetis (NYSE:ZTS)
Historical Stock Chart
From Jul 2023 to Jul 2024